A Prospective Phase Ⅱ Clinical Study of Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer That Has Failed Trastuzumab Therapy
Latest Information Update: 14 Jul 2022
At a glance
- Drugs Pyrotinib (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 07 Jun 2022 Results assessing efficacy and safety of oral pyrotinib in combination with oral metronomic vinorelbine in patients with HER2-positive advanced breast cancer who had failed prior trastuzumab-based therapy presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 06 Apr 2022 Status changed from recruiting to completed.
- 01 Jun 2021 New trial record